Kraig Biocraft Laboratories Announces Selective Breeding Advancement, Significantly Increasing Both Spider Silk Production Throughput and Hybrid Vigor
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a selective breeding advancement that materially increases recombinant spider silk production throughput. By mating an improved parental strain with a BAM-1 parent, the Company created the BAM-1 Alpha hybrid, which demonstrated 22% higher cocoon shell weight (the company's measure of silk output) and an increase in hybrid vigor of more than 245% versus the original BAM-1. BAM-1 Alpha will be deployed across Kraig's multi-facility production infrastructure to support commercial manufacturing and lower per-unit production cost, while robustness data beyond shell weight remains unquantified.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha annunciato un avanzamento nell'allevamento selettivo che aumenta significativamente la throughput della produzione di seta di ragno ricombinante. Accoppiando una linea genitore migliorata con un genitore BAM-1, l'azienda ha creato l'ibrido BAM-1 Alpha, che ha dimostrato un aumento del 22% nel peso della cera del bozzolo (la misura di output della seta dell'azienda) e un incremento della fertilità ibrida di oltre 245% rispetto all'originale BAM-1. BAM-1 Alpha verrà distribuito sull'infrastruttura di produzione multi-impianto di Kraig per supportare la produzione commerciale e ridurre il costo di produzione per unità, mentre i dati sulla robustezza oltre al peso del bozzolo restano non quantificati.
Kraig Biocraft Laboratories (OTCQB: KBLB) anunció un avance de crianza selectiva que aumenta de manera significativa el rendimiento de la producción de seda de araña recombinante. Al aparear una cepa parental mejorada con un progenitor BAM-1, la Compañía creó el híbrido BAM-1 Alpha, que demostró un 22% más alto peso de la envoltura del capullo (la medida de salida de seda de la empresa) y un aumento de la vigor híbrido de más del 245% frente al BAM-1 original. BAM-1 Alpha se implementará en la infraestructura de producción multi-plantas de Kraig para apoyar la fabricación comercial y reducir el costo de producción por unidad, mientras que los datos de robustez más allá del peso de la envoltura no están cuantificados.
Kraig Biocraft Laboratories (OTCQB: KBLB)가 재조합 거미줄 생산량의 처리량을 실질적으로 증가시키는 선택적 육종 발전을 발표했습니다. 향상된 모체 계통과 BAM-1 계통을 교배하여 BAM-1 Alpha 하이브리드를 만들었고, 이는 22% 더 높은 고치 껍질 무게(회사의 섬유 출력 척도)와 원래 BAM-1에 비해 하이브리드 활력 증가가 245% 이상임을 보여주었습니다. BAM-1 Alpha는 Kraig의 다중 시설 생산 인프라에 배치되어 상업적 제조를 지원하고 단위당 생산 비용을 낮출 것이며, 껍질 무게를 넘는 로버스트니스 데이터는 아직 정량화되지 않았습니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a annoncé une avancée de sélection qui augmente significativement le débit de production de soie d'araignée recombinante. En croisant une souche parentale améliorée avec un parent BAM-1, l'entreprise a créé l'hybride BAM-1 Alpha, qui a montré une augmentation de 22% du poids de la coque du cocon (la mesure de sortie de soie de l'entreprise) et une hausse de la vigueur hybride de plus de 245% par rapport au BAM-1 d'origine. BAM-1 Alpha sera déployé dans l'infrastructure de production multi-sites de Kraig pour soutenir la fabrication commerciale et réduire le coût de production par unité, tandis que les données de robustesse au-delà du poids de la coque restent non quantifiées.
Kraig Biocraft Laboratories (OTCQB: KBLB) kündigte eine fortschrittliche Zuchtmethode an, die die Durchsatzmenge der Produktion von rekombinanter Spinnenfaden deutlich erhöht. Durch das Kreuzung einer verbesserten elterlichen Stammlinie mit einem BAM-1-Elterlichen hat das Unternehmen den Hybrid BAM-1 Alpha geschaffen, der 22% mehr Kokon-Schalengewicht (die messbare Seidenausbeute des Unternehmens) und eine Zunahme der hybriden Vitalität von mehr als 245% gegenüber dem ursprünglichen BAM-1 zeigte. BAM-1 Alpha wird in die multi-Standorte-Produktionsinfrastruktur von Kraig integriert, um die kommerzielle Fertigung zu unterstützen und die Stückkosten zu senken, während Robustheitsdaten über das Schalengewicht hinaus noch nicht quantifiziert sind.
مختبرات Kraig Biocraft (OTCQB: KBLB) أعلنت عن تقدم في التربية الانتقائية يزيد بشكل ملموس من معدل إنتاج خيوط العنكبوت المعاد تركيبها. من خلال تزويج سلالة أبوية محسّنة مع والد BAM-1، أنشأت الشركة الهجين BAM-1 Alpha، الذي أظهر زيادة بنسبة 22% في وزن الغلاف الشرعي للشرنقة (مقياس الشركة لإنتاج الخيوط) وزيادة في قوة الهجين بأكثر من 245% مقارنة بـ BAM-1 الأصل. سيتم نشر BAM-1 Alpha عبر بنية الإنتاج متعددة المنشآت في Kraig لدعم التصنيع التجاري وخفض تكلفة الإنتاج للوحدة، بينما تبقى بيانات المتانة بخلاف وزن الغلاف غير مُقَيَّمة.
Kraig Biocraft Laboratories (OTCQB: KBLB)宣布在选择性育种方面取得进展，实质性提高了重组蜘蛛丝的产量。通过让改良的亲本系与 BAM-1 亲本进行杂交，公司创造了 BAM-1 Alpha 杂交体，该杂交体在“茧壳重量”（公司衡量丝输出的指标）方面提升了 22%，与原始 BAM-1 相比，杂交优势提高超过 245%。BAM-1 Alpha 将在 Kraig 的多设施生产基础设施中部署，以支持商业制造并降低单位生产成本，同时超出茧壳重量的鲁棒性数据尚未量化。
- Cocoon shell weight increased by 22%
- Hybrid vigor improved by more than 245% versus BAM-1
- BAM-1 Alpha designated as production hybrid for deployment
- Robustness improvements not yet quantified beyond cocoon size
- Claims of lower production cost are unquantified in the release
ANN ARBOR, Mich., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig” or "Kraig Labs"), a world leader in spider silk technology*, is proud to announce the Company has succeeded in significantly increasing the production throughput of its recombinant spider silk production platform.
This increase is the successful result of the Company's continuous work in the selective breeding of parental strains for its production hybrid silkworms, which is the basis of its recombinant spider silk production system. Kraig's first successful hybrid, designated the BAM-1, demonstrated hybrid vigor, which increased both cocoon shell weight (a critical measure of silk output) and robustness. That hybrid was created by mating two genetically divergent parental strains. The fielding of the BAM-1 was a major improvement in spider silk production technology.
Over the past two years, Kraig Labs has used selective breeding to create more advanced parental strains with the goal of increasing hybrid vigor to further increase shell weight. One of these new advanced strains was specifically designed as a replacement for one of the original BAM-1 parental strains.
By mating the strongest of the BAM-1 parental strains with the new advanced strain, Kraig Labs has demonstrated measurable hybrid vigor (as measured by cocoon shell weight) of
"Our small team of researchers continues to outperform our competitors in spider silk R&D and commercial development. The creation of our new BAM-1 Alpha hybrid is the product of our focused vision for large-scale commercialization of spider silk and the dedication of our geneticists to that vision," said Kim Thompson, Founder and CEO of Kraig Labs. "Frankly, the
Kraig Labs utilizes its proprietary genetically enhanced silkworm technology platform to produce recombinant spider silk. These silkworms spin recombinant spider silk fibers naturally within their cocoons, combining the scalability of traditional sericulture with the superior performance of spider silk proteins.
With BAM-1 Alpha now moving into commercial deployment, Kraig Labs will leverage its multi-facility production infrastructure to integrate this enhanced production hybrid into ongoing manufacturing. This advancement supports the Company's vision of delivering high-performance spider silk fibers for applications spanning performance textiles, defense, medical, and industrial markets.
This latest development underscores Kraig Labs' commitment to continuous innovation and its leadership in developing scalable bioengineered materials inspired by nature's toughest fibers.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What production improvement did Kraig Labs announce on October 13, 2025 for KBLB?
How will the BAM-1 Alpha hybrid affect KBLB's manufacturing?
Does Kraig provide robustness or durability data for BAM-1 Alpha (KBLB)?
What metric did Kraig use to measure the BAM-1 Alpha improvement for KBLB?
Will BAM-1 Alpha be used commercially by Kraig (KBLB) immediately?
